10. CONFLICT OF INTEREST
All members of the Testicular Cancer Guidelines working group have provided disclosure statements of all relationships that they have that might be perceived as a potential source of a conflict of interest. This information is provided below and is also publicly available on the EAU website: https://uroweb.org/guidelines/testicular-cancer.
This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation, and funding is limited to administrative and travel and meeting expenses. No honoraria or other reimbursements have been provided.
Disclosures: The EAU Guidelines Office certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/ affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: A. Heidenreich reported receiving company speaker honorarium or consultant fees from Astella Germany, Bayer HealthCare, Janssen-Cilag and Novartis Radiopharmaceuticals GmbH. J.Boormans reported research collaborations with Johnson & Johnson, MSD, VitroScan, Merc Serono and Merck AG; receiving consultancy or speaker’s fees from Johnson & Johnson, BMS, AstraZeneca, MSD, Ismar Healthcare, Merck AG/Pfizer and Bayer, Springer Media, Congress Care and NLC Health; book writing for Bohn Stafleu van Loghum. C. Fankhauser reported receiving company speaker honoraria or consultant fees from Janssen, Novartis, MiR detect, Johnson and Johnson and Pfizer, and receiving funding from Gilead, MSD, Astellas, Pangea, Unilabs, Natera and MiR detect. C. Oing reported receiving honoraria from Sandoz, Berufsverband Deutscher Internistinem und Internisten and Springer Nature Publishing; fulfilling advisory roles for Sandoz, Pfizer, Astex Pharmaceuticals and RareCan. S. Fischer reported receiving company speaker honoraria from Johnson & Johnson; travel grants from Bayer; research support from Astellas and MSD, and consultation fees from AMGEN. D. Berney, R. Leão, A. Patrikidou, T. Tandstad, H. Haugnes, A. Papachristofilou, J. Lobo, D. Di Nardo, R. Cornes, W. Cazzaniga, C. Gravina, F. Janisch and Y. Jain have nothing to declare.